|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A SERD- or SSH-palbociclib combination has therapeutic potential in breast tumors resistant to endocrine therapies or those expressing ESR1 mutations.
|
25991817 |
2015 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A similar magnitude suggestive association, although nonstatistically significant, was found between Val(80) polymorphism and estrogen receptor-negative status of the breast tumors.
|
19366906 |
2009 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A total of 499 estrogen receptor-positive primary breast tumor specimens of advanced disease patients treated with first-line tamoxifen were genotyped for CYP2C19*2 and *17 variant alleles, with primary end point time-to-treatment failure (TTF).
|
21830868 |
2011 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A tumor microarray of 94 estrogen receptor-positive human breast tumors correlated coexpression of MUC1 and IFITM1 with poor recurrence-free survival, poor overall survival, and AI-resistance.
|
30655323 |
2019 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells.
|
18310281 |
2008 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
About 70% of breast tumors express estrogen receptor alpha (ERα), which mediates the proliferative effects of estrogens on breast epithelial cells, and are candidates for treatment with antiestrogens, steroidal or non-steroidal molecules designed to compete with estrogens and antagonize ERs.
|
27729460 |
2017 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
About 75-80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic.
|
28320353 |
2017 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.
|
30859501 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Acetylation additionally increased the stability of p68 and p72 RNA helicase and stimulated their ability to coactivate the estrogen receptor, thereby potentially contributing to its aberrant activation in breast tumors.
|
20663877 |
2010 |
|
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
|
24185510 |
2013 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
|
24185510 |
2013 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
|
24185510 |
2013 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Activating mutations of PIK3CA are the most frequent genomic alterations in estrogen receptor (ER)-positive breast tumors, and selective phosphatidylinositol 3-kinase α (PI3Kα) inhibitors are in clinical development.
|
25877889 |
2015 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
|
16585219 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Active and passive smoking, IL6, ESR1, and breast cancer risk.
|
17594514 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Additionally, we found elevated binding of the estrogen receptor (ER) in H-ras ER element in all pairs of ovarian tumor/normal tissue tested, whereas in ER-negative control breast tumor/normal tissue pairs, no differences in ER DNA-binding levels were observed.
|
8878453 |
1996 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Aggressive, basal-like, ER-negative breast tumors occur in younger women, African-American women, women who carry BRCA1 mutation, and women exposed to ionizing radiation.
|
23325583 |
2013 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
AGR3 expression in breast tumours is significantly associated with oestrogen receptor α (P<0.001) and lower tumour grade (P<0.01).
|
25875093 |
2015 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
AIB1 and CCND1 amplifications may, thus, represent two different subsets of ER-positive breast tumors.
|
9865902 |
1998 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
All anti-estrogen treated breast tumors lost the estrogen receptor expression in the brain metastases, whereas no Her2/neu conversions occurred after treatment with trastuzumab.
|
28870906 |
2017 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Also, the amount of immunostained nuclei for RelB (P = 0.025) and NFkB1 (P = 0.031) was higher in ER- breast tumors versus ER+ breast tumors.
|
16740744 |
2006 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Also, the overexpression of miR-34b inhibited ER+ breast tumor growth in an orthotopic mammary fat pad xenograft mouse model.
|
22113133 |
2011 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women.
|
10815765 |
2000 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Altered expression of estrogen receptor-alpha variant messenger RNAs between adjacent normal breast and breast tumor tissues.
|
11400682 |
2000 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Although tamoxifen treatment is associated with improved survival in patients with estrogen receptor (ER)-positive breast tumors, resistance remains an important clinical obstacle.
|
20689759 |
2010 |